These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 35941674)
1. Selection and validation of chemotherapy beneficiaries among elderly nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated radiation therapy (IMRT): a large real-world study. Wu YL; Yang KB; Huang Y; Shi JR; He QS; Chen L; Li WF; Huang XD; Lin L; Chen YP; Mao YP; Tang LL; Ma J Radiat Oncol; 2022 Aug; 17(1):138. PubMed ID: 35941674 [TBL] [Abstract][Full Text] [Related]
2. Induction or adjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in paediatric nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA. Liang YJ; Wen DX; Luo MJ; Tang LQ; Guo SS; Wang P; Chen QY; Liu LT; Mai HQ Eur J Cancer; 2021 Dec; 159():133-143. PubMed ID: 34743068 [TBL] [Abstract][Full Text] [Related]
3. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study. Guo SS; Tang LQ; Chen QY; Zhang L; Liu LT; Guo L; Mo HY; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Wang L; Lv X; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ Oncotarget; 2016 May; 7(20):29739-48. PubMed ID: 27105538 [TBL] [Abstract][Full Text] [Related]
4. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort. Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417 [TBL] [Abstract][Full Text] [Related]
5. Risk stratification and beneficiary selection among elderly nasopharyngeal carcinoma patients from concurrent chemoradiotherapy combined with induction chemotherapy. He S; Wu YL; Gao Y; He D; Huang Y Cancer Med; 2023 May; 12(9):10536-10552. PubMed ID: 37062057 [TBL] [Abstract][Full Text] [Related]
6. Prognostic value of circulating Epstein-Barr virus DNA level post-induction chemotherapy for patients with nasopharyngeal carcinoma: A recursive partitioning risk stratification analysis. Kong FF; Pan GS; Du CR; Ni MS; Zhai RP; He XY; Shen CY; Lu XG; Hu CS; Ying HM Radiother Oncol; 2023 Aug; 185():109721. PubMed ID: 37244356 [TBL] [Abstract][Full Text] [Related]
7. Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in advanced-stage nasopharyngeal carcinoma. Chen FP; Luo YS; Chen K; Li JY; Huo LQ; Shi L; Ou-Yang Y; Cao XP Eur J Cancer; 2021 Jul; 151():63-71. PubMed ID: 33964573 [TBL] [Abstract][Full Text] [Related]
8. Induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus volumetric modulated arc therapy alone in the treatment of stage II-IVB nasopharyngeal carcinoma patients: a retrospective controlled study. Liu L; Fei Z; Chen M; Zhao L; Su H; Gu D; Lin B; Cai X; Lu L; Gao M; Ye X; Jin X; Xie C Radiat Oncol; 2018 Aug; 13(1):148. PubMed ID: 30103765 [TBL] [Abstract][Full Text] [Related]
9. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study. Wei Z; Zhang Z; Luo J; Li N; Peng X J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162 [TBL] [Abstract][Full Text] [Related]
10. Individualized Concurrent Chemotherapy for Patients with Stage III-IVa Nasopharyngeal Carcinoma Receiving Neoadjuvant Chemotherapy Combined with Definitive Intensity-Modulated Radiotherapy. Ji P; Lu Q; Chen X; Chen Y; Peng X; Chen Z; Lin C; Lin S; Zong J Cancer Res Treat; 2023 Oct; 55(4):1113-1122. PubMed ID: 37170497 [TBL] [Abstract][Full Text] [Related]
11. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma. Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466 [TBL] [Abstract][Full Text] [Related]
12. Can Epstein-Barr virus-deoxyribonucleic acid load after induction chemotherapy combined with American Joint Committee on Cancer stage determine the chemotherapy intensity of locally advanced nasopharyngeal carcinoma? Zhang Q; Peng ZW; Gu ZS; Wang Y; He F; Zhao WB; Luo W; Mei YY Cancer Med; 2023 Jan; 12(1):223-235. PubMed ID: 35674137 [TBL] [Abstract][Full Text] [Related]
13. Selection and Validation of Induction Chemotherapy Beneficiaries Among Patients With T3N0, T3N1, T4N0 Nasopharyngeal Carcinoma Using Epstein-Barr Virus DNA: A Joint Analysis of Real-World and Clinical Trial Data. Xu C; Zhang S; Li WF; Chen L; Mao YP; Guo Y; Liu Q; Ma J; Tang LL Front Oncol; 2019; 9():1343. PubMed ID: 31850226 [No Abstract] [Full Text] [Related]
14. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status. Peng H; Chen L; Zhang Y; Guo R; Li WF; Mao YP; Tan LL; Sun Y; Zhang F; Liu LZ; Tian L; Lin AH; Ma J Oncotarget; 2016 Apr; 7(17):24208-16. PubMed ID: 27008701 [TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in elderly patients with stage III-IVa nasopharyngeal carcinoma: A real-world study based on medical comorbidities. Jin YN; Xiao ZW; Yao W; Yu J; Zhang WJ; Marks T; Zhang HY; Yao JJ; Xia LP Head Neck; 2024 Aug; 46(8):2020-2030. PubMed ID: 38366693 [TBL] [Abstract][Full Text] [Related]
16. Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy. Hui EP; Li WF; Ma BB; Lam WKJ; Chan KCA; Mo F; Ai QYH; King AD; Wong CH; Guo R; Poon DMC; Tong M; Li L; Lau TKH; Wong KCW; Lam DCM; Lo YMD; Ma J; Chan ATC Ann Oncol; 2020 Jun; 31(6):769-779. PubMed ID: 32217076 [TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant or Adjuvant Chemotherapy Plus Concurrent CRT Versus Concurrent CRT Alone in the Treatment of Nasopharyngeal Carcinoma: A Study Based on EBV DNA. Liu LT; Chen QY; Tang LQ; Guo SS; Guo L; Mo HY; Li Y; Tang QN; Sun XS; Liang YJ; Zhao C; Guo X; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ J Natl Compr Canc Netw; 2019 Jun; 17(6):703-710. PubMed ID: 31200353 [TBL] [Abstract][Full Text] [Related]
18. Prognostic model on overall survival in elderly nasopharyngeal carcinoma patients: a recursive partitioning analysis identifying pre-treatment risk stratification. Li Y; Weng Y; Huang Z; Pan Y; Cai S; Ding Q; Wu Z; Chen X; Lu J; Hu D; Qiu S Radiat Oncol; 2023 Jun; 18(1):104. PubMed ID: 37353800 [TBL] [Abstract][Full Text] [Related]
19. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients receiving additional induction chemotherapy. Lv JW; Qi ZY; Zhou GQ; He XJ; Chen YP; Mao YP; Chen L; Tang LL; Li WF; Lin AH; Ma J; Sun Y Cancer Sci; 2018 Mar; 109(3):751-763. PubMed ID: 29266526 [TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus neoadjuvant chemotherapy plus concurrent chemoradiotherapy for ascending or descending types of nasopharyngeal carcinoma: A retrospective study. Lin Q; Lu L; Wang X; Lin Y; Chen Y; Chen H; Chen S; Lin S; Zhang Y; Zheng P; Chen X Am J Otolaryngol; 2022; 43(1):103193. PubMed ID: 34509080 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]